This Article Full Text Full Text (PDF) All Versions of this Article: 42/4/542    most recent 01.HYP.0000092440.52239.39v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, R. Articles by Horiuchi, M. Search for Related Content PubMed PubMed Citation Articles by Chen, R. Articles by Horiuchi, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE Related Collections ACE/Angiotension receptors

(Hypertension. 2003;42:542.)
© 2003 American Heart Association, Inc.

Scientific Contributions

Important Role of Nitric Oxide in the Effect of Angiotensin-Converting Enzyme Inhibitor Imidapril on Vascular Injury

Rui Chen; Masaru Iwai; Lan Wu; Jun Suzuki; Li-Juan Min; Tetsuya Shiuchi; Takashi Sugaya; Hong-Wei Liu; Tai-Xing Cui; Masatsugu Horiuchi

From the Department of Medical Biochemistry, Ehime University School of Medicine (R.C., M.I., L.W., J.S., L.-J.M., T.Shiuchi, H.-W.L., T.-X.C., M.H.), Shigenobu, Ehime, Japan; and Discovery Research Laboratory, Tanabe Seiyaku Co (T.Sugaya), Osaka, Japan.

Correspondence to Dr Masatsugu Horiuchi, Department of Medical Biochemistry, Ehime University School of Medicine, Shigenobu, Onsen-gun, Ehime 791–0295, Japan. E-mail horiuchi{at}m.ehime-u.ac.jp

To examine the possible role of the bradykinin-NO system in the action of ACE inhibitors, we studied the effects of imidapril, an ACE inhibitor, on inflammatory vascular injury by using AT₁a-receptor–deficient (AT₁aKO) mice. A polyethylene cuff was placed around the femoral artery of AT₁aKO mice and wild-type (WT; C57BL/6J) mice. Neointimal area in cross sections of the artery was measured 14 days after cuff placement. A low dose of imidapril (1 mg/kg per day), which did not affect blood pressure, was administered by gavage. Expression of monocyte chemoattractant protein (MCP)-1 and tumor necrosis factor (TNF)- was detected by immunohistochemical staining and reverse transcriptase–polymerase chain reaction (RT-PCR) 7 days after the operation. Neointimal formation, vascular smooth muscle cell proliferation, and expression of MCP-1 and TNF- were attenuated in the injured artery in AT₁aKO mice compared with those in WT mice. Imidapril inhibited neointimal formation, DNA synthesis of vascular smooth muscle cells, and expression of MCP-1 and TNF- in AT₁aKO mice as well as in WT mice. In addition, imidapril increased tissue cGMP content after cuff placement. These inhibitory effects of imidapril were significantly reduced or abolished by a bradykinin receptor antagonist, Hoechst 140, or an NO synthase inhibitor, L-NAME, both in WT and AT₁aKO mice. Treatment with imidapril did not change AT₂ receptor and ACE expression detected by RT-PCR in the injured artery. These results indicate that not only blockade of angiotensin II production but also activation of the bradykinin-NO system plays an important role in the beneficial effects of imidapril on vascular remodeling.

Key Words: nitric oxide • angiotensin • vasculature • arteries

This article has been cited by other articles:

				S. Hagita, M. Osaka, K. Shimokado, and M. Yoshida Oxidative Stress in Mononuclear Cells Plays a Dominant Role in Their Adhesion to Mouse Femoral Artery After Injury Hypertension, March 1, 2008; 51(3): 797 - 802. [Abstract] [Full Text] [PDF]

				P. Li, T. Kondo, Y. Numaguchi, K. Kobayashi, M. Aoki, N. Inoue, K. Okumura, and T. Murohara Role of Bradykinin, Nitric Oxide, and Angiotensin II Type 2 Receptor in Imidapril-Induced Angiogenesis Hypertension, February 1, 2008; 51(2): 252 - 258. [Abstract] [Full Text] [PDF]

				D. Fukuda, M. Sata, N. Ishizaka, and R. Nagai Critical Role of Bone Marrow Angiotensin II Type 1 Receptor in the Pathogenesis of Atherosclerosis in Apolipoprotein E Deficient Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 90 - 96. [Abstract] [Full Text] [PDF]

				C. Kojima, A. Kawakami, T. Takei, K. Nitta, and M. Yoshida Angiotensin-Converting Enzyme Inhibitor Attenuates Monocyte Adhesion to Vascular Endothelium through Modulation of Intracellular Zinc J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 855 - 860. [Abstract] [Full Text] [PDF]

				S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]

				A. Oshita, M. Iwai, R. Chen, A. Ide, M. Okumura, S. Fukunaga, T. Yoshii, M. Mogi, J. Higaki, and M. Horiuchi Attenuation of Inflammatory Vascular Remodeling by Angiotensin II Type 1 Receptor-Associated Protein Hypertension, October 1, 2006; 48(4): 671 - 676. [Abstract] [Full Text] [PDF]

				X.-L. Tian, Y. M. Pinto, O. Costerousse, W. M. Franz, A. Lippoldt, S. Hoffmann, T. Unger, and M. Paul Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats Hum. Mol. Genet., July 15, 2004; 13(14): 1441 - 1450. [Abstract] [Full Text] [PDF]

				T. Jinno, M. Iwai, Z. Li, J.-M. Li, H.-W. Liu, T.-X. Cui, H. Rakugi, T. Ogihara, and M. Horiuchi Calcium Channel Blocker Azelnidipine Enhances Vascular Protective Effects of AT1 Receptor Blocker Olmesartan Hypertension, February 1, 2004; 43(2): 263 - 269. [Abstract] [Full Text] [PDF]